Tasquinimod
An immunomodulator with a unique mechanism of action for myelofibrosisUnder development for the treatment of hematological cancers, is in clinical Phase Ib/IIa development for the treatment of myelofibrosis.
Our Projects
Fully owned projects
Discovery
Preclinical
Phase I
Phase II
Phase III
Hematological malignancies
- Tasquinimod – Myelofibrosis
Partners:HOVONEurope
- Tasquinimod – Myelofibrosis
Partners:The University of TexasMD AndersonCancer CenterUSA
- Tasquinimod – Multiple Myeloma
Partners:Abramson Cancer CenterUSA
Inflammatory eye disorders
- Laquinimod – Eye Drops, Ocular Biodistribution
Partners:Stanford MedicineGorcUSA
Licensed projects
Discovery
Preclinical
Phase I
Phase II
Phase III
Solid tumors
- Naptumomab – Combination with anti-PDL1 (durvalumab) in solid tumors
Partners:NeoTXAstraZeneca
Laquinimod
A groundbreaking eye drop treatment for posterior uveitisDeveloped for the treatment of severe eye diseases, such as non-infectious posterior uveitis. Ready for clinical Phase II. Activities to establish commercial partnerships are ongoing.
Naptumomab
A tumor targeting immunotherapy that enhances the ability of the immune system to recognize and kill the tumorNaptumomab estafenatox (naptumomab) is a tumor targeting immunotherapy that enhances the ability of the immune system to recognize and kill the tumor. Naptumomab is developed for treatment of solid tumors by Active Biotech’s partner NeoTX.
